Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma · line 1 · Acalabrutinib monotherapy (continuous, until progression or intolerance)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-ACALABRUTINIB-CONTINUOUS`

ID	`IND-CLL-1L-BTKI`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-CLL`
Sources	`SRC-CLL14-FISCHER-2019` `SRC-ELEVATE-TN-SHARMAN-2020` `SRC-ESMO-CLL-2024` `SRC-NCCN-BCELL-2025`

Notes

STUB — pending Co-Lead sign-off. Standard track for CLL 1L. Engine routes high-risk (RF-CLL-HIGH-RISK) toward IND-CLL-1L-VENO time-limited.

Used By

Algorithms

ALGO-CLL-1L - ALGO-CLL-1L

Indication

IND-CLL-1L-ZANUBRUTINIB - IND-CLL-1L-ZANUBRUTINIB

Questionnaires

QUEST-CLL-1L - Chronic Lymphocytic Leukemia / SLL — first line